Lu AG06466 in Patients With Post Traumatic Stress Disorder (PTSD)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- PTSD
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 55 years
- Gender
- Both males and females
Description
The crossover study consists of two treatment periods of 15 days duration. On Day 1 of Treatment Period 1, eligible patients will be randomised (1:1) to a sequence of treatments (either Lu AG06466-placebo or placebo-Lu AG06466). 15 patients are planned per sequence.
The crossover study consists of two treatment periods of 15 days duration. On Day 1 of Treatment Period 1, eligible patients will be randomised (1:1) to a sequence of treatments (either Lu AG06466-placebo or placebo-Lu AG06466). 15 patients are planned per sequence.
Tracking Information
- NCT #
- NCT04597450
- Collaborators
- Not Provided
- Investigators
- Study Director: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@Lundbeck.com
Get Well Soon